EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Evox Therapeutics landed a deal with Takeda. The agreement will see Takeda pay up to $44 million (€40 million) in upfront fees, near-term milestones and research funding in return for access to up to five protein replacement and mRNA therapies. Release  

> Synairgen raised £14 million to run a COVID-19 trial. The British biotech recently got clearance to test its inhaled formulation of interferon-beta-1a in patients with the coronavirus. Statement

> AstraZeneca expanded its collaboration with Schrödinger. The new deal covers biologics, not just small molecules. Release 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

> Vaccitech and the University of Oxford shared phase 2a data on prostate cancer immunotherapy VTP-800. Based on early evidence that VTP-800 enhances the efficacy of checkpoint inhibitors, the British biotech plans to move the candidate into a larger midphase trial. Statement  

> Themis joined a collaborative effort to develop a vaccine against COVID-19. The Institut Pasteur is leading the consortium. Release 

> Freeline appointed Julie Krop as chief medical officer. Krop has previously worked at companies including Pfizer and Vertex. Statement 

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.